Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US.

Key Points

• This research aims to evaluate the operational efficiency of using one versus multiple bispecific antibodies for treating lymphomas.
• Comparative analysis of treatment options for diffuse large B-cell lymphoma and follicular lymphoma.
• Assessment of time and cost savings associated with single versus multiple bispecific antibodies.
• Using a single bispecific antibody is predicted to lead to significant cost savings.
• A single bsAb may improve time efficiency in oncology practices.